While it is well understood that timely access to treatment is key for the management of rheumatic diseases, respondents to The American College of Rheumatology (ACR) 2019 Rheumatic Disease Patient Survey reported difficulty accessing and paying for their therapies in the past year.
While it is well understood that timely access to treatment is key for the management of rheumatic diseases, respondents to The American College of Rheumatology (ACR) 2019 Rheumatic Disease Patient Survey reported difficulty accessing and paying for their therapies in the past year.
The survey, which was conducted online in June of 2019 among a nationally representative sample of 1517 adults with rheumatic disease, sheds additional light on findings from last year’s 2018 Rheumatic Disease Report Card, which graded individual US states on patients’ ability to live well with rheumatic disease.
One key finding of this year’s survey is that step therapy is being widely employed as a utilization management tool. Step therapy is a strategy under which which less expensive drugs must be administered and found to be ineffective before a patient gains access to higher-cost drugs, often including biologics and their biosimilars. In total, 46.49% of patients said they had been required to undergo step therapy in the past year. Patients in Kentucky, Tennessee, Mississippi, Alabama, New York, New Jersey, and Pennsylvania were more likely to be subject to step therapy than those who lived elsewhere, and approximately half of all men receiving treatment were required to undergo step therapy.
These findings concerning step therapy are particularly notable given that, starting this year, CMS implemented a change allowing Medicare Advantage plans to use step therapy for Part B drugs. According to the ACR in a statement issued earlier this year, “Step therapy has resulted in forced drug switching, treatment gaps, and cessation of effective therapy.” Downstream effects, the group added, include uncontrolled disease, disability, and increased healthcare costs.
The cost of care was indeed a key issue for respondents in this year’s survey; 57.13% of patients said they had difficulty affording their therapy in the past year. Affordability concerns were not limited to the uninsured; while 90.16% of patients were insured, 56.98% of patients with insurance said they had difficulty affording their treatments. In total, 25.10% of patients reported that their out-of-pocket spending was higher than $1000, and 6.24% said their spending exceeded $5000 each year. Among those who had insurance, 23.76% paid more than $1000 out of pocket for their medication every year.
Additionally, 57.41% of patients said they were being seen by or had been referred to a rheumatologist, but 63.68% had to wait more than 30 days to receive an initial appointment, and 39.58% had to wait between 31 days and 60 days.
“These findings make clear that Americans living with rheumatic disease—regardless of age, gender, or income level—struggle to find affordable care," said Paula Marchetta, MD, MBA, president of the ACR. “To address these challenges, it is crucial for patients, clinicians, and policymakers to work together to improve access to rheumatology care so that patients can live longer, healthier, and more fulfilling lives.”
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.